Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Intangibles (2016 - 2025)

Historic Intangibles for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $117.1 million.

  • Vanda Pharmaceuticals' Intangibles rose 262.32% to $117.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $117.1 million, marking a year-over-year increase of 262.32%. This contributed to the annual value of $117.1 million for FY2025, which is 262.32% up from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Intangibles of $117.1 million as of Q4 2025, which was up 262.32% from $108.8 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Intangibles registered a high of $121.4 million during Q4 2023, and its lowest value of $17.4 million during Q3 2023.
  • Over the past 5 years, Vanda Pharmaceuticals' median Intangibles value was $21.0 million (recorded in 2021), while the average stood at $62.5 million.
  • In the last 5 years, Vanda Pharmaceuticals' Intangibles tumbled by 800.25% in 2023 and then soared by 56472.34% in 2024.
  • Over the past 5 years, Vanda Pharmaceuticals' Intangibles (Quarter) stood at $20.1 million in 2021, then fell by 7.55% to $18.6 million in 2022, then surged by 553.75% to $121.4 million in 2023, then dropped by 5.99% to $114.1 million in 2024, then rose by 2.62% to $117.1 million in 2025.
  • Its last three reported values are $117.1 million in Q4 2025, $108.8 million for Q3 2025, and $110.6 million during Q2 2025.